UPDATE: Needham & Company Starts Taysha Gene Therapies (TSHA) at Buy, $45 PT

July 15, 2021 4:16 PM EDT
Get Alerts TSHA Hot Sheet
Price: $12.98 --0%

Rating Summary:
    10 Buy, 1 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 5 | New: 12
Trade Now! 
Join SI Premium – FREE
(Updated - July 15, 2021 4:53 PM EDT)

Needham & Company analyst Gil Blum initiates coverage on Taysha Gene Therapies (NASDAQ: TSHA) with a Buy rating and a price target of $45.00.

The analyst commented, "Taysha leverages AAV9, a well-validated delivery platform for gene therapy across a host of CNS indications. AAV9 is the carrier vector in the only FDA approved gene therapy for a CNS indication, Zolgensma. Relying on a tried and true delivery platform for all the company’s programs reduces overall development risk as well as providing rapid access to commercial grade materials. This also allows for more development flexibility, enabling the application of novel payloads such as regulated genes, vectorized RNA and mini-genes. Taysha's Giant Axonal Neuropathy (GAN) program offers potential near term catalysts that could be validating for the platform. Additional data and regulatory updates are expected in 2H:21. We are initiating TSHA at a BUY and a $45 Target."

For an analyst ratings summary and ratings history on Taysha Gene Therapies click here. For more ratings news on Taysha Gene Therapies click here.

Shares of Taysha Gene Therapies closed at $20.50 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Needham & Company, FDA